oral glp 1 drugs With FDA approval of Wegovy pill, new era of GLP-1 weight loss begins Ro Launches Wegovy® Pill Through

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

or oral administration

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models

More recent evidence is expanding their benefits to heart failure with preserved ejection fraction and clinically important renal outcomes in patients with and without diabetes

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

Consultancy sees the active GLP-1 user population rising by as much as 50% by 2027.